The prostate cancer news has been very “light” for the past few days. Even today’s new reports offer very little new information. Some examples of recent published data are as follows:
Freedland et al. have reported that, in the Duke series of prostate cancer patients, there is evidence that obese men undergoing radical prostatectomy had higher-grade and larger tumors than non-obese patients, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers — but these data are not definitive.
A report by Goldenberg et al. discusses the relative potential merits of drugs like dutasteride (which blocks 5-alpha reductase enzymes types 1 and 2) as compared to drugs like finasteride (which blocks only 5-alpha reductase enzyme type 2) on prostate cancer prevention and treatment.
Chi et al. have reviewed available information on development-stage, targeted drugs for the treatment of castration-resistant prostate cancer.
All in all, there has been no new data in the past few days that adds significantly to current knowledge — which is why news reports on this site have been relatively “light” in the past week.
Filed under: Drugs in development, Management, Prevention, Risk, Treatment
Search for new and
ongoing trials on the
CTAG PCa web site
